Yokota et al. demonstrated that EGFR-TKI-resistant NSCLC organoids may respond to combination treatment of the Bcl-2 inhibitor navitoclax and the survivin inhibitor YM-155, and that BRAFG469A-mutated organoids were suppressed by a combination treatment of trametinib and erlotinib [18]. Here, EGFR is linked to non-small cell lung carcinoma.